Default company panoramic image

Naegis Pharmaceuticals Inc.

Discovering new and safer ways to treat serious inflammatory diseases that impact hundreds of millions of patients worldwide.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Vancouver, BC, Canada
  • Currency CAD
  • Founded February 2009
  • Employees 4
  • Website

Company Summary

Applying the most recent understanding of targets in arachidonic acid signaling pathways to discover and develop novel therapeutics for serious inflammatory diseases for which current treatment options are limited by lack of efficacy or poor side effect profile.

Focused on two proprietary programs:
PALI (peptidase augmentor, leukotriene inhibitor) - oral therapy for Chronic Obstructive Pulmonary Disease (COPD), a serious lung disease with high mortality affecting over 200 million globally, and prevalence increasing by 10% over the next decade
LTSI (leukotriene synthesis inhibitor) - topical therapy for uveitis, a condition that is responsible for some 10% of the legal blindness in the US and for which there are limited therapeutic options

Advancing towards near-term, high-value milestones.

Led by an experienced management team with demonstrated success and a Board of Directors composed of industry leaders.


  • Default avatar
    Dr. David Burgoyne

  • Default avatar
    Dr. John Langlands
    Vice President, Preclinical Research


  • Default avatar
    Catherine Wade, Dentons Canada LLP
    Default avatar
    Goldsmith & Poulos LLP